These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26238166)

  • 1. The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis.
    Vollmer T; Signorovitch J; Huynh L; Galebach P; Kelley C; DiBernardo A; Sasane R
    J Neurol Sci; 2015 Oct; 357(1-2):8-18. PubMed ID: 26238166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.
    De Stefano N; Giorgio A; Battaglini M; Rovaris M; Sormani MP; Barkhof F; Korteweg T; Enzinger C; Fazekas F; Calabrese M; Dinacci D; Tedeschi G; Gass A; Montalban X; Rovira A; Thompson A; Comi G; Miller DH; Filippi M
    Neurology; 2010 Jun; 74(23):1868-76. PubMed ID: 20530323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice.
    Pichler A; Khalil M; Langkammer C; Pinter D; Bachmaier G; Ropele S; Fuchs S; Enzinger C; Fazekas F
    Mult Scler; 2016 Mar; 22(3):340-6. PubMed ID: 26163072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aging and Brain Atrophy in Multiple Sclerosis.
    Ghione E; Bergsland N; Dwyer MG; Hagemeier J; Jakimovski D; Paunkoski I; Ramasamy DP; Carl E; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
    J Neuroimaging; 2019 Jul; 29(4):527-535. PubMed ID: 31074192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis.
    Jasperse B; Minneboo A; de Groot V; Kalkers NF; van Helden PE; Uitdehaag BM; Barkhof F; Polman CH
    Arch Neurol; 2007 Feb; 64(2):190-4. PubMed ID: 17296834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.
    De Stefano N; Stromillo ML; Giorgio A; Bartolozzi ML; Battaglini M; Baldini M; Portaccio E; Amato MP; Sormani MP
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):93-9. PubMed ID: 25904813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study.
    Jacobsen C; Hagemeier J; Myhr KM; Nyland H; Lode K; Bergsland N; Ramasamy DP; Dalaker TO; Larsen JP; Farbu E; Zivadinov R
    J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1109-15. PubMed ID: 24554101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis.
    Branger P; Parienti JJ; Sormani MP; Defer G
    PLoS One; 2016; 11(3):e0149685. PubMed ID: 26983008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial.
    Filippi M; Rovaris M; Inglese M; Barkhof F; De Stefano N; Smith S; Comi G
    Lancet; 2004 Oct 23-29; 364(9444):1489-96. PubMed ID: 15500893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
    Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
    J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics.
    Vidal-Jordana A; Sastre-Garriga J; Pérez-Miralles F; Pareto D; Rio J; Auger C; Tintoré M; Rovira A; Montalban X
    J Neuroimaging; 2016 Sep; 26(5):532-8. PubMed ID: 26935253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.
    Magraner M; Coret F; Casanova B
    Eur J Radiol; 2012 Nov; 81(11):3485-90. PubMed ID: 22391507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of early brain atrophy in clinically isolated syndromes.
    Pérez-Miralles F; Sastre-Garriga J; Tintoré M; Arrambide G; Nos C; Perkal H; Río J; Edo MC; Horga A; Castilló J; Auger C; Huerga E; Rovira A; Montalban X
    Mult Scler; 2013 Dec; 19(14):1878-86. PubMed ID: 23652215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis.
    Fritz DA; Dwyer MG; Bagnato F; Watts KL; Bratina A; Zorzon M; Durastanti V; Locatelli L; Millefiorini E; Zivadinov R
    Neurol Res; 2006 Apr; 28(3):275-9. PubMed ID: 16687053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.
    Barkhof F; de Jong R; Sfikas N; de Vera A; Francis G; Cohen J;
    Mult Scler; 2014 Nov; 20(13):1704-13. PubMed ID: 24812043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.
    Tsivgoulis G; Katsanos AH; Grigoriadis N; Hadjigeorgiou GM; Heliopoulos I; Kilidireas C; Voumvourakis K
    PLoS One; 2015; 10(3):e0116511. PubMed ID: 25756363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis.
    Lee H; Narayanan S; Brown RA; Chen JT; Atkins HL; Freedman MS; Arnold DL
    Mult Scler; 2017 Mar; 23(3):420-431. PubMed ID: 27246142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study.
    Gentile G; Mattiesing RM; Brouwer I; van Schijndel RA; Uitdehaag BMJ; Twisk JWR; Kappos L; Freedman MS; Comi G; Jack D; Barkhof F; De Stefano N; Vrenken H; Battaglini M
    Neuroimage Clin; 2023; 38():103397. PubMed ID: 37086648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.
    Mellergård J; Tisell A; Blystad I; Grönqvist A; Blennow K; Olsson B; Dahle C; Vrethem M; Lundberg P; Ernerudh J
    Eur J Neurol; 2017 Jan; 24(1):112-121. PubMed ID: 27699930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.